Development and Validation of the Quantification of GML-1 Compound ( N -benzyl- N -methyl-1-phenylpyrrolo[1,2- A ] pyrazine- 3-carbamide) in the Blood Plasma of Rats by HPLC–MS

A. A. Novitskiy; P. O. Bochkov; A. A. Litvin; V. P. Zherdev; E. V. Blynskaya

doi:10.3103/S0027131418010042

Development and Validation of the Quantification of GML-1 Compound (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-A] pyrazine- 3-carbamide) in the Blood Plasma of Rats by HPLC–MS

作者: Novitskiy A.A.¹, Bochkov P.O.¹, Litvin A.A.¹, Zherdev V.P.¹, Blynskaya E.V.¹
隶属关系:
1. Zakusov Institute of Pharmacology
期: 卷 72, 编号 6 (2017)
页面: 322-324
栏目: Article
URL: https://journal-vniispk.ru/0027-1314/article/view/163557
DOI: https://doi.org/10.3103/S0027131418010042
ID: 163557

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
作者简介
参考
补充文件
统计

详细

The technique of quantitative determination of a new compound, possessing anxiolytic activity, GML-1 in the blood plasma of rats is developed and validated. The analysis is performed by HPLC–MS. The method is linear in the range of 50–1000 ng/mL. 83.63% of GML-1 was recovered. The detection limit was 25 ng/mL.